EUVIMEDEUVIMED entdecken
Open Access

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study

Niels M R van der Sangen, Bimmer E P M Claessen, I Tarik Küçük, Alexander W den Hartog, Jan Baan, Marcel A M Beijk, Ronak Delewi, Tim P van de Hoef, Paul Knaapen, Jorrit S Lemkes, Koen M Marques, Alexander Nap und 6 weitere

EuroIntervention · 2023

DOI: 10.4244/eij-d-22-00886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EuroIntervention, 2023. Verfasst von Niels M R van der Sangen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Myocardial Infarction. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Early P2Y12 inhibitor monotherapy has emerged as a promising alternative to 12 months of dual antiplatelet therapy following percutaneous coronary intervention (PCI). AIMS: In this single-arm pilot study, we evaluated the feasibility and safety of ticagrelor or prasugrel monotherapy directly following PCI in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). METHODS: Patients received a loading dose of ticagrelor or prasugrel before undergoing platelet function testing and subsequent PCI using new-generation drug-eluting stents. The stent result was adjudicated with optical coherence tomography in the first 35 patients. Ticagrelor or prasugrel monotherapy was continued for 12 months. The primary ischaemic endpoint was the composite of all-cause mortality, myocardial infarction, definite or probable stent thrombosis or stroke within 6 months. The primary bleeding endpoint was Bleeding Academic Research Consortium type 2, 3 or 5 bleeding within 6 months. RESULTS: From March 2021 to March 2022, 125 patients were enrolled, of whom 75 ultimately met all in- and exclusion criteria (mean age 64.5 years, 29.3% women). Overall, 70 out of 75 (93.3%) patients were treated with ticagrelor or prasugrel monotherapy directly following PCI. The primary ischaemic endpoint occurred in 3 (4.0%) patients within 6 months. No cases of stent thrombosis or spontaneous myocardial infarction occurred. The primary bleeding endpoint occurred in 7 (9.3%) patients within 6 months. CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionMyocardial InfarctionHumansFemaleMiddle AgedMalePlatelet Aggregation InhibitorsPrasugrel HydrochlorideTicagrelorPilot ProjectsHemorrhageTreatment Outcome

Substanzen

Platelet Aggregation InhibitorsPrasugrel HydrochlorideTicagrelor

Autor:innen und Institutionen

  • Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
  • Department of Cardiology, Amsterdam UMC, Vrije University (VU), Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.

Zitieren

APA

van der Sangen, N. M. R., Claessen, B. E. P. M., Küçük, I. T., den Hartog, A. W., Baan, J., Beijk, M. A. M., Delewi, R., van de Hoef, T. P., Knaapen, P., Lemkes, J. S., Marques, K. M., Nap, A., Verouden, N. J. W., Vis, M. M., de Winter, R. J., Kikkert, W. J., Appelman, Y., & Henriques, J. P. S. (2023). Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study. EuroIntervention. https://doi.org/10.4244/eij-d-22-00886

Vancouver

van der Sangen NMR, Claessen BEPM, Küçük IT, den Hartog AW, Baan J, Beijk MAM, et al. Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study. EuroIntervention. 2023. doi:10.4244/eij-d-22-00886

BibTeX
@article{vanderSangen2023,
  author = {van der Sangen, Niels M R and Claessen, Bimmer E P M and Küçük, I Tarik and den Hartog, Alexander W and Baan, Jan and Beijk, Marcel A M and Delewi, Ronak and van de Hoef, Tim P and Knaapen, Paul and Lemkes, Jorrit S and Marques, Koen M and Nap, Alexander and Verouden, Niels J W and Vis, M Marije and de Winter, Robbert J and Kikkert, Wouter J and Appelman, Yolande and Henriques, Jose P S},
  title = {Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study},
  journal = {EuroIntervention},
  year = {2023},
  doi = {10.4244/eij-d-22-00886}
}
Kostenlos starten →